PT Kalbe Financials
| PTKFF Stock | USD 0.1 0.00 0.00% |
PTKFF |
Understanding current and past PT Kalbe Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of PT Kalbe's financial statements are interrelated, with each one affecting the others. For example, an increase in PT Kalbe's assets may result in an increase in income on the income statement.
PT Kalbe Stock Summary
PT Kalbe competes with Sanofi ADR, Bristol Myers, AstraZeneca PLC, Gilead Sciences, and Novartis. PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia. PT Kalbe operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 12501 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Gedung KALBE, Jakarta, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Benchmark | Dow Jones Industrial |
| Website | www.kalbe.co.id |
| Phone | 62 21 4287 3888 |
| Currency | USD - US Dollar |
PT Kalbe Key Financial Ratios
There are many critical financial ratios that PT Kalbe's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that PT Kalbe Farma reports annually and quarterly.| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Beta | 0.32 | |||
| Z Score | 1.0 |
PTKFF Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PT Kalbe's current stock value. Our valuation model uses many indicators to compare PT Kalbe value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PT Kalbe competition to find correlations between indicators driving PT Kalbe's intrinsic value. More Info.PT Kalbe Farma is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for PT Kalbe Farma is roughly 1.58 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PT Kalbe's earnings, one of the primary drivers of an investment's value.PT Kalbe Farma Systematic Risk
PT Kalbe's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PT Kalbe volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on PT Kalbe Farma correlated with the market. If Beta is less than 0 PT Kalbe generally moves in the opposite direction as compared to the market. If PT Kalbe Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PT Kalbe Farma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PT Kalbe is generally in the same direction as the market. If Beta > 1 PT Kalbe moves generally in the same direction as, but more than the movement of the benchmark.
PT Kalbe November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PT Kalbe help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PT Kalbe Farma. We use our internally-developed statistical techniques to arrive at the intrinsic value of PT Kalbe Farma based on widely used predictive technical indicators. In general, we focus on analyzing PTKFF Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PT Kalbe's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 26.95 |
Complementary Tools for PTKFF Pink Sheet analysis
When running PT Kalbe's price analysis, check to measure PT Kalbe's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PT Kalbe is operating at the current time. Most of PT Kalbe's value examination focuses on studying past and present price action to predict the probability of PT Kalbe's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PT Kalbe's price. Additionally, you may evaluate how the addition of PT Kalbe to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |